natgillin/translations-raw huggingface dataset:
To reduce the risk of resistance, Hepsera must be used in combination with another anti-hepatitis B medicine that does not cause resistance in the same way as Hepsera.
Za zmanjšanje tveganja za razvoj odpornosti se mora zdravilo Hepsera uporabljati skupaj z drugim zdravilom proti hepatitisu B, ki ne povzroča takšnega razvoja odpornosti kot zdravilo Hepsera.
The most common side effects with Hepsera (seen in more than 1 patient in 10) are raised creatinine (a marker of kidney problems) and asthenia (weakness).
Najpogostejša neželena učinka zdravila Hepsera (opažena pri več kot 1 bolniku od 10) sta zvišana raven kreatinina (označevalca težav z jetri) in astenija (šibkost).
Hepsera was more effective than placebo in slowing down the progression of liver disease.
Zdravilo Hepsera je bilo pri upočasnitvi napredovanja bolezni jeter učinkovitejše od placeba.
For the full list of all side effects reported with Hepsera, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Hepsera, glejte navodilo za uporabo.
Why has Hepsera been approved?
Zakaj je bilo zdravilo Hepsera odobreno?
Hepsera must not be used in people who are hypersensitive (allergic) to adefovir dipivoxil or any of the other ingredients.
Zdravila Hepsera ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) dipivoksiladefovirat ali katero koli drugo sestavino zdravila.
Adefovir interferes with the action of a viral enzyme called DNA polymerase, which is involved in the formation of viral DNA.
Adefovir ovira delovanje virusnega encima DNK-polimeraza, ki je udeležen pri tvorbi virusne DNK.
The active substance in Hepsera, adefovir dipivoxil, is a ‘prodrug' that is converted into adefovir in the body.
Zdravilna učinkovina v zdravilu Hepsera, dipivoksiladefovirat, je predzdravilo, ki se v telesu pretvori v adefovir.
Treatment with Hepsera should be started by a doctor who has experience in the management of chronic hepatitis B. The recommended dose is 10 mg once a day.
Zdravljenje z zdravilom Hepsera mora uvesti zdravnik, ki ima izkušnje z zdravljenjem kroničnega hepatitisa B. Priporočeni odmerek je ena 10-miligramska tableta enkrat na dan. Trajanje zdravljenja je odvisno od bolnikovega stanja in odziva na zdravljenje.
Hepsera is a medicine that contains the active substance adefovir dipivoxil.
Hepsera je zdravilo, ki vsebuje zdravilno učinkovino dipivoksiladefovirat.
What is Hepsera?
Kaj je zdravilo Hepsera?
How has Hepsera been studied?
Kako je bilo zdravilo Hepsera raziskano?
What is Hepsera used for?
Za kaj se zdravilo Hepsera uporablja?
How is Hepsera used?
Kako se zdravilo Hepsera uporablja?
How does Hepsera work?
Kako zdravilo Hepsera deluje?
Hepsera is not recommended for use in patients with severe kidney disease or who are on dialysis (a blood clearing technique) - its use should only be considered in these patients if its potential benefits are greater than its potential risks.
Uporaba zdravila Hepsera ni priporočljiva pri bolnikih s hudim obolenjem ledvic ali tistih, ki so na dializi (tehniki čiščenja krvi).
This procedure started on 21 August 2006 and ended on 20 October 2006.
Ta postopek se je začel dne 21. avgusta 2006 in končal dne 20. oktobra 2006.
In conclusion, CVMP is of the opinion that:
Mnenje odbora CVMP v zaključku je:
(Immunisation schedules are given in the product information.)
(Sheme za imunizacijo so podane v informacijah o zdravilu.)
Cattle Intramuscular injection.
Govedo Intramuskularna injekcija.
One dose = 2 ml
En odmerek = 2 ml
7.e.13 Hungary
7.e.13 Madžarska
The procedure started on 13 March
Postopek se je začel dne 13. marca 2006.
Per 2 ml dose:
Na 2 ml odmerka:
On the contrary it is known that extremely high numbers of samples must be tested in order to detect a low level of defects.
Na drugi strani je znano, da je treba testirati izjemno veliko število vzorcev, da bi lahko zaznali majhno število okvar.
The first renewal procedure for the vaccine was finalised in June 2004.
Prvi postopek za podaljšanje dovoljenja za cepivo se je končal junija leta 2004.
In March 2006 Intervet then submitted an application for a marketing authorisation for this vaccine following a repeat use mutual recognition procedure, with Germany acting as Reference Member State, for Denmark, Poland, Slovakia and Slovenia.
Podjetje Intervet je nato marca leta 2006 vložilo prošnjo za dovoljenje za promet s tem cepivom in ponovno uporabilo postopek medsebojnega priznavanja, pri čemer je Nemčija bila referenčna država članica za Dansko, Poljsko, Slovaško in Slovenijo.
It is worthy of note that the first EU marketing authorisation for Bovilis BVD was granted in 1998, and the vaccine is currently authorised in 14 EU Member States.
Vredno je omeniti, da je bilo prvo dovoljenje za promet z zdravilom Bovilis BVD v EU odobreno leta 1998, cepivo pa je trenutno odobreno v 14 državah članicah EU.
DK-2740 Skovlunde Denmark
DK-2740 Skovlunde Danska
The initial mutual recognition procedure was finalised on 24 June 1999, and 11 other Member States authorised the product at this time.
Začetni postopek medsebojnega priznavanja se je končal dne 24. junija 1999, zdravilo pa je takrat odobrilo 11 drugih držav članic.
The factors which determine the safety of a product are the measures applied in the production and control procedures.
Faktorji, ki določajo varnost proizvoda, so merila, ki jih je treba upoštevati pri proizvodnji in nadzornih postopkih.
There is always a small risk of extraneous agent contamination from a variety of sources.
Vedno pa obstaja majhna stopnja tveganja kontaminacije s tujimi snovmi iz velikega števila virov.
CY-1665 Nicosia Cyprus
CY-1665 Nicosia Ciper
The production and testing of Bovilis BVD vaccine are in accordance with the relevant requirements of Directive 2001/82/EC, the relevant EU guidelines and the relevant monographs of the Ph.Eur.
Postopek proizvodnje in testiranje cepiva Bovilis BVD sta v skladu z ustreznimi zahtevami Direktive 2001/82/ES, ustreznimi smernicami EU in ustreznimi monografijami evropske farmakopeje.
B-2800 Mechelen Belgium
B-2800 Mechelen Belgija
• extraneous agents testing of raw materials are carried out according to the relevant requirements
• da se testiranja surovin na prisotnost tujih snovi izvaja v skladu z ustreznimi zahtevami,
The added value of retesting for this feature in inactivated viral vaccines is extremely small.
Dodana vrednost ponovnega testiranja zaradi tega pojava v inaktiviranih virusnih cepivih je izredno majhna.
Foot and Mouth virus is virtually exotic to Western Europe and Bluetongue, although of a recent change in status, is not ubiquitous or endemic in the majority of the EU, so for these 2 agents the practical risks should be lower.
Virus slinavke in parkljevke je za zahodno Evropo skorajda eksotičen, bolezen modrikastega jezika pa kljub nedavnim spremembam v statusu ni vseprisotna ali endemična v večini EU, tako da bi moralo biti praktično tveganje v primeru teh dveh snovi nižje.
Intervet International Podruznica
Intervet International Podružnica
The extra testing (which requires the use of animals) would therefore be a disproportionate measure when balanced against the positive effects which can be obtained for this vaccine.
Dodatno testiranje (kjer je treba uporabiti živali) bi bilo tako nesorazmeren ukrep, če bi ga primerjali s pozitivnimi učinki, ki bi jih lahko imelo to cepivo.
ES-37080 Salamanca Spain
ES-37080 Salamanca Španija
Based on the current requirements and the relevant safeguards (e.g., GMP) the CVMP concludes that the Applicant has taken adequate measures to guarantee the quality and safety of Bovilis BVD.
Na osnovi trenutnih zahtev in ustreznih zaščitnih ukrepov (npr. DPP - dobra proizvodna praksa), je CVMP zaključil, da je vlagatelj izvedel ustrezne ukrepe, s katerimi lahko zagotavlja kakovost in varnost zdravila Bovilis BVD.
Consequently Germany notified the EMEA, on 31 October 2006, that the CMD(v) failed to reach an agreement regarding Bovilis BVD.
Dne 31. oktobra je Nemčija obvestila agencijo EMEA, da CMD(v) ni uspel doseči soglasja glede zdravila Bovilis BVD.
The CMD(v) could not reach an agreement by day 60 of this procedure, as to where Denmark maintained their concerns.
CMD(v) do 60. dne tega postopka ni mogel doseči soglasja glede dejstva, ker je imela Danska še vedno iste zadržke.
Bovilis BVD was first authorised in Germany on 6 May 1998 (as Bovilis BVD-MD).
Zdravilo Bovilis BVD je bilo najprej odobreno v Nemčiji dne 6. maja 1998 (pod imenom Bovilis BVD-MD).
The probability that any such contamination would be identified in the test proposed by the Danish Medicines Agency is even smaller.
Možnost, da bi s testi lahko odkrili tako kontaminacijo, kot je predlagala Danska agencija za zdravila, je še manjša.
Wybrzeze Gdynskie 6c PL-01-531 Warszawa Poland
Wybrzeze Gdynskie 6c PL-01-531 Warszawa Poljska
DE-85716 Unterschleissheim Germany
DE-85716 Unterschleissheim Nemčija
At day 90 of the MRP, 2 August 2006, Denmark could not agree to the granting of a marketing authorization as they considered the product to present a potential serious risk for animal health.
Na 90. dan postopka medsebojnega priznavanja, dne 2. avgusta 2006, Danska ni mogla privoliti v odobritev dovoljenja za promet, ker je zdravilo štela za morebitno nevarno za zdravje živali.
3, Paparigopoulou Street GR-152 32 Halandri Athens Greece
3, Paparigopoulou Street GR-152 32 Halandri Athens Grčija
Intervet Portuguesa Ltd. Estrada Nacional 249, Km 14,2 PT-2725-397 Mem Martins Codes
Portugalska Intervet Portuguesa Ltd. Estrada Nacional 249, Km 14,2 PT-2725-397 Mem Martins Codes
The Marketing Authorisation Holder should provide all supporting data to justify a positive benefit-risk ratio for the treated animal.
Imetnik dovoljenja za promet z zdravilom bi moral priskrbeti vse podatke, ki govorijo v prid pozitivnemu razmerju med koristmi in tveganji pri zdravljenih živalih.
The matter was referred to the Co-ordination Group for Mutual Recognition and Decentralised Procedures, CMD(v), for a 60 day procedure in accordance with Article 33(1) of Directive 2001/82/EC, as amended.
Zadeva je bila posredovana koordinacijski skupini za medsebojno priznavanje in decentralizirane postopke, CMD(v), v 60 dni dolg postopek v skladu s členom 33(1) Direktive 2001/82/ES z vsemi spremembami.
With regard to the potential benefit or otherwise from conducting additional tests, it is known that the efficiency of final batch testing in revealing defects is highly variable, depending on the type of defect, and that it is preferable to build quality into the whole process rather than rely on end product testing.
Kar se tiče morebitnih koristi in ostalega glede izvajanja dodatnih testov pa je znano, da je učinkovitost testiranja končnih serij z namenom odkrivanja okvar zelo spremenljiva in odvisna od vrste okvar in da je bolje napraviti kakovost za sestavni del celotnega postopka, kot pa se zanašati na testiranje končnega proizvoda.
Intervet Bulgaria EOOD 7, Iskarsko shoes blvd BG-1528 Sofia Bulgaria
Intervet Bulgaria EOOD 7, Iskarsko shoes blvd BG-1528 Sofia Bolgarija
FR-49071 Beaucouzé Cedex France
FR-49071 Beaucouzé Cedex Francija
50 ELISA units, inducing ≥ 4.6 log2 VN units
50 enot ELISA, vključno z ≥ 4.6 log2 enot NT
Member State Applicant or Marketing Authorisation Holder
Vlagatelj ali imetnik dovoljenja za promet z zdravilom
Considering all the measures taken, it is very unlikely that any contamination of Bovilis BVD could firstly occur, and secondly that such contamination would eventually lead to seroconversion, even in a small number of vaccinated animals.
Glede na vsa privzeta merila je zelo malo verjetno, da bi najprej prišlo do kontaminacije zdravila Bovilis BVD in da bi nato taka kontaminacija nazadnje privedla do serokonverzije, celo pri majhnem številu cepljenih živali.
There are many years of experience with the use of this vaccine, and there are no known adverse reactions associated with the vaccine.
Kljub mnogoletnim izkušnjam z uporabo tega cepiva ni znanih neželenih učinkov, ki bi jih povezovali s tem cepivom.
As the likelihood of contamination of Bovilis BVD vaccine, and the subsequent probability of seroconversion by such contaminants is extremely low, the advantage of additional final product testing for extraneous agents (serological method) is considered to be negligible.
Ker je verjetnost kontaminacije cepiva Bovilis BVD in posledična verjetnost serokonverzije zaradi takih kontaminantov izjemno nizka, se štejejo koristi dodatnega testiranja končnih proizvodov na prisotnost tujih snovi (serološka metoda) za zanemarljive.
The CVMP has concluded that the risk/benefit for Bovilis BVD is favourable.
CVMP je zaključil, da je razmerje med koristmi in tveganji za zdravilo Bovilis BVD ugodno.
Therefore the Danish testing requirement is considered to be unjustified.
Zaradi tega šteje Odbor zahtevo Danske glede dodatnih testiranj za neutemeljeno.
The risk of accidental contamination with FMDV, IBRV, BLV and BTV is concluded to be low; consequently the risk of seroconversion against the listed agents is also concluded to be low.
Tveganje za nenamerno kontaminacijo s FMDV, IBRV, BLV in BTV je bilo ocenjeno kot nizko; posledično se sklepa, da je tveganje serokonverzije v prisotnosti navedenih snovi prav tako nizko.
Denmark considers that the proposed testing regime to demonstrate freedom from extraneous agents is insufficient to ensure that Bovilis BVD would not interfere with their national eradication campaigns for certain animal diseases and that therefore the benefit: risk assessment for Bovilis BVD is negative and authorisation of the product would represent a potential serious risk to animal health.
Danska je bila mnenja, da predlagan režim testiranj za dokazovanje odsotnosti tujih snovi ne zadostuje za zagotavljanje, da zdravilo Bovilis BVD ne bo motilo njenih nacionalnih eradikacijskih programov proti določenim živalskim boleznim, zaradi česar je bila ocena razmerja med koristmi in tveganji v primeru zdravila Bovilis BVD negativna, odobritev dovoljenja za promet z zdravilom pa bi predstavljala morebitno resno tveganje za zdravje živali.
• the production of Bovilis BVD vaccine is in compliance with GMP requirements
• da je proizvodnja cepiva Bovilis BVD v skladu z zahtevami smernic DPP,
Therefore the requested additional specified extraneous testing requirement is scientifically not justified for Bovilis BVD.
Zato zahteva po dodatnem specificiranem testiranju na vsebnost tujih snovi v primeru zdravila Bovilis BVD znanstveno ni utemeljena.
No scientific arguments are available concerning how the additional testing would minimise the risk of possible seroconversion induced by the vaccine.
kako naj bi dodatno testiranje zmanjšalo tveganje za morebitno serokonverzijo, ki bi jo sprožilo cepivo.
Krizna 10
Križna 10
Although the consequences of an accidental seroconversion against the listed extraneous agents would damage the animal health status of a country free from the four specified diseases, the benefit: risk evaluation remains positive due to the low risk of contamination of the product.
Čeprav bi bile posledice nenamerne serokonverzije zaradi prisotnosti navedenih tujih snovi poslabšanje zdravstvenega stanja živali v državi, kjer ni prisotnih omenjenih štirih vrst bolezni, pa bi ostala ocena razmerja med koristmi in tveganji pozitivna zaradi nizkega tveganja za kontaminacijo proizvoda.
SK-040 01 Kosice Slovak Republic Tel: +421 (55) 676 9405 Fax: +421 (55) 676 9873
SK-040 01 Kosice Slovaška republika Tel: +421 (55) 676 9405 Faks: +421 (55) 676 9873
During its meeting of November 2006, the CVMP started a referral procedure under Article 33(4) of Directive 2001/82/EC as amended for Bovilis BVD.
Med srečanjem novembra 2006 je odbor CVMP začel z napotitvenim postopkom glede zdravila Bovilis BVD v skladu s členom 33(4) Direktive 2001/82/ES z vsemi spremembami.
The application was made in accordance with Article 12.3 of Directive 2001/82/EC as a stand alone application.
Vloga je bila izdelana v skladu s členom 12(3) Direktive 2001/82/ES za samostojno zdravilo.
Czech Republic Tel: +420 (2) 333 440 25 Fax: +420 (2) 333 440 22
Češka republika Tel: +420 (2) 333 440 25 Faks: +420 (2) 333 440 22
Pursuant to Article 33(4) of Council Directive 2001/82/EC, as amended, the matter has been referred to CVMP.
Zadeva je bila v skladu s členom 33(4) Direktive Sveta 2001/82/ES z vsemi spremembami, predana Odboru za zdravila za uporabo v veterinarski medicini (CVMP).
The benefits of Bovilis BVD vaccine are accepted.
Koristi zdravila Bovilis BVD so priznani.
• extraneous agents testing of finished batches of Bovilis BVD for FMDV, BLV, BTV and IBRV is not required in the relevant monographs
• da zahtev po testiranju končnih serij zdravila Bovilis BVD na prisotnost virusa slinavke in parkljevke, virusa goveje levkemije, virusa bolezni modrikastega jezika in virusa infekcioznega bovinega rinotraheitisa glede na ustrezne monografkse publikacije ni potrebno.
BLV and IBRV are more ubiquitous but the measures summarised below have generally been accepted in the majority of member states to be adequate to ensure negligible risk.
Virus goveje levkemije (BLV) in virus infekcioznega bovinega rinotraheitisa (IBRV) sta bolj vseprisotna, vendar pa je večina članic, kot zadostne za zagotovitev zanemarljivo majhnega tveganja, sprejela spodaj navedena merila: V splošnem je mogoče odsotnost tujih snovi v cepivih zagotoviti z:
monographs for inactivated bovine vaccines and have written to the EDQM and asked them to address this.
Odbor CVMP je ugotovil neskladnosti (pri testiranju na prisotnost tujih snovi) v monografijah evropske farmakopeje v primeru neaktiviranih cepiv za govedo, o katerih je EDQM (Evropskemu direktoratu za kakovost zdravil) podal pisno prošnjo za odgovor na vprašanje.
Intervet International B.V. Wim de Korverstraat 35 NL-5831 AN Boxmeer The Netherlands Tel: + 31 485 587 652
NL-5831 AN Boxmeer Nizozemska
In general, the absence of extraneous agents in vaccines can be ensured by: GMP compliance of the production system Extraneous agents testing of raw materials Extraneous agents testing of batches of finished product, if required.
testiranjem serij končnih proizvodov na prisotnost tujih snovi, če je potrebno.
It is available as tablets (20 mg; 40 and 80 mg).
Na voljo je v obliki tablet (20, 40 in 80 mg).
The European Commission granted a marketing authorisation valid throughout the European Union for Telmisartan Actavis on 30 September 2010.
Evropska komisija je dovoljenje za promet z zdravilom Telmisartan Actavis, veljavno po vsej Evropski uniji, izdala 30. septembra 2010.
pressure is not reached, the dose can be increased to 80 mg, or another medicine for hypertension can be added, such as hydrochlorothiazide.
se ciljni krvni tlak ne doseže, se lahko odmerek zviša na 80 mg ali pa doda še eno zdravilo proti hipertenziji, kot je hidroklorotiazid.
For more information about treatment with Telmisartan Actavis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Telmisartan Actavis preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
This means that Telmisartan Actavis is similar to a ‘reference medicine' already authorised in the European Union (EU) called Micardis.
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Micardis.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Telmisartan Actavis.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
This allows the blood pressure to drop, reducing the risks associated with high blood pressure, such as having a heart attack or stroke.
To povzroči padec krvnega tlaka in zmanjšanje tveganja, ki je povezano z visokim krvnim tlakom, kot sta srčni infarkt ali kap.
The doctor should monitor the patient's blood pressure closely when starting Telmisartan Actavis, and may decide to adjust the patient's blood pressure-lowering medication.
Zdravnik mora med uvajanjem zdravila Telmisartan Actavis skrbno spremljati bolnikov krvni tlak in se lahko odloči za prilagoditev odmerka zdravila za zniževanje bolnikovega krvnega tlaka.
Telmisartan Actavis is used to treat essential hypertension (high blood pressure) in adults.
Zdravilo Telmisartan Actavis se uporablja za zdravljenje esencialne hipertenzije (visokega krvnega tlaka) pri odraslih.
Because Telmisartan Actavis is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je Telmisartan Actavis generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
This is a summary of the European public assessment report (EPAR) for Telmisartan Actavis.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Telmisartan Actavis.
The full EPAR for Telmisartan Actavis can be found on the Agency's website EMA website/Find medicine/Human medicines/European Public Assessment Reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Telmisartan Actavis je na voljo na spletni strani agencije EMA website/Find medicine/Human medicines/European Public Assessment Reports.
It also allows the heart to pump blood more easily, which can help to reduce the risk of future cardiovascular problems.
Hkrati srcu olajša črpanje krvi, kar pripomore k zmanjšanju tveganja za pojav srčno-žilnih težav v prihodnosti.
What are the benefits and risks of Telmisartan Actavis?
Kakšne so koristi in tveganja, povezani z zdravilom Telmisartan Actavis?
The active substance in Telmisartan Actavis, telmisartan, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Zdravilna učinkovina v zdravilu Telmisartan Actavis, telmisartan, je antagonist receptorja angiotenzina II, kar pomeni, da preprečuje delovanje hormona v telesu, ki mu pravimo angiotenzin II.
For the treatment of essential hypertension, the usual recommended dose of Telmisartan Actavis is 40 mg once a day, but some patients may benefit from using 20 mg once a day.
Za zdravljenje esencialne hipertenzije znaša običajni priporočeni odmerek zdravila Telmisartan Actavis 40 mg enkrat dnevno, vendar pa lahko nekaterim bolnikom zadostuje že 20-miligramski odmerek.
The CHMP concluded that, in accordance with EU requirements, Telmisartan Actavis has been shown to have comparable quality and to be bioequivalent to Micardis.
CHMP je zaključil, da je bilo za zdravilo Telmisartan Actavis v skladu z zahtevami EU dokazano, da ima primerljivo raven kakovosti kot zdravilo Micardis ter da mu je biološko enakovredno.
Telmisartan Actavis is also used to prevent cardiovascular problems (problems with the heart and blood vessels) such as heart attacks or strokes.
Zdravilo Telmisartan Actavis se uporablja tudi za preprečevanje srčno-žilnih težav (težav s srcem in ožiljem), kot sta srčni infarkt in možganska kap.
Telmisartan Actavis is a ‘generic medicine'.
Zdravilo Telmisartan Actavis je „generično zdravilo“.
Because Telmisartan Actavis is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Micardis.
Ker je Telmisartan Actavis generično zdravilo, so bile študije pri bolnikih omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Micardis.
By blocking the receptors to which angiotensin II normally attaches, telmisartan stops the hormone having an effect, allowing the blood vessels to widen.
Telmisartan z zaviranjem receptorjev, na katere se angiotenzin II običajno veže, prepreči učinek hormona, kar privede do razširitve žil.
The Committee recommended that Telmisartan Actavis be given marketing authorisation.
Priporočil je, da se za zdravilo Telmisartan Actavis izda dovoljenje za promet.